Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Autoimmune Disorders

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 122 articles: HTML format

Single Articles

November 2024
1. BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al
   Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
   Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145.
   PubMed     Abstract available
   
   
   
2. CABALLERO-AVILA M, Martin-Aguilar L, Pascual-Goni E, Michael MR, et al
   Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
   Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142.
   PubMed     Abstract available
   
   
   
3. PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al
   Increased Disability Progression in rs10191329(AA) Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
   Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144.
   PubMed     Abstract available
   
   
   
4. MEUTH SG, Wolff S, Muck A, Willison A, et al
   Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
   Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143.
   PubMed     Abstract available
   
   
   October 2024
5. WANG W, Yin J
   Coexistence of Acute Cerebral Infarction and Reversible Posterior Encephalopathy Syndrome in a Patient with Hashimoto's Thyroiditis.
   Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27120.
   PubMed    
   
   
   
6. JANG Y, Hong SE, Ahn SH, Mon SY, et al
   Polygenic Landscape of Cryptogenic New-Onset Refractory Status Epilepticus: A Comprehensive Whole-Genome Sequencing Study.
   Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27100.
   PubMed     Abstract available
   
   
   
7. ALZAMANAN F, Ding Y, Harroud A
   Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
   Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112.
   PubMed     Abstract available
   
   
   
8. MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al
   RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
   Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114.
   PubMed     Abstract available
   
   
   
9. BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al
   Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
   Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096.
   PubMed     Abstract available
   
   
   
10. SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al
    Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102.
    PubMed     Abstract available
    
    
    
11. MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al
    Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
    Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093.
    PubMed     Abstract available
    
    
    
12. SUZUKI S, Utsugisawa K
    MuSK-Myasthenia Gravis and Cancer.
    Ann Neurol. 2024 Oct 8. doi: 10.1002/ana.27094.
    PubMed    
    
    
    
13. FALSO S, Iorio R
    Reply to "MuSK-Myasthenia Gravis and Cancer".
    Ann Neurol. 2024 Oct 4. doi: 10.1002/ana.27091.
    PubMed    
    
    
    September 2024
14. FADDA G, Banwell B, Elliott C, Fetco D, et al
    Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.
    Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066.
    PubMed     Abstract available
    
    
    August 2024
15. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
    Ann Neurol. 2024;96:302-305.
    PubMed     Abstract available
    
    
    July 2024
16. MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al
    Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.
    Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043.
    PubMed     Abstract available
    
    
    
17. SCALFARI A, Traboulsee A, Oh J, Airas L, et al
    Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
    Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034.
    PubMed     Abstract available
    
    
    
18. FALSO S, Gessi M, Marini S, Benvenuto R, et al
    Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology.
    Ann Neurol. 2024 Jul 15. doi: 10.1002/ana.27033.
    PubMed     Abstract available
    
    
    
19. HU Y, Frisell T, Alping P, Song H, et al
    Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
    PubMed     Abstract available
    
    
    
20. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    PubMed     Abstract available
    
    
    
21. GUO A, Zhang Z, Dong GH, Su L, et al
    Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2024;96:194-203.
    PubMed     Abstract available
    
    
    June 2024
22. PIEHL F, Alping P, Virtanen S, Englund S, et al
    COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
    PubMed     Abstract available
    
    
    May 2024
23. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    PubMed     Abstract available
    
    
    
24. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    PubMed     Abstract available
    
    
    April 2024
25. GILLIGAN M, Lesnick CE, Guo Y, Bradshaw MJ, et al
    Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis.
    Ann Neurol. 2024 Apr 18. doi: 10.1002/ana.26943.
    PubMed     Abstract available
    
    
    
26. CALABRESE M, Preziosa P, Scalfari A, Colato E, et al
    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
    Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913.
    PubMed     Abstract available
    
    
    March 2024
27. NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al
    HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
    Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921.
    PubMed     Abstract available
    
    
    
28. ALPING P, Neovius M, Piehl F, Frisell T, et al
    Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
    Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
    PubMed     Abstract available
    
    
    
29. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    PubMed     Abstract available
    
    
    February 2024
30. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    PubMed     Abstract available
    
    
    
31. SHU Y, Huang R, Li Q, Lu Y, et al
    Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Is Associated with HLA-A*3303 and HLA-DPB1*0501.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26899.
    PubMed     Abstract available
    
    
    
32. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    PubMed     Abstract available
    
    
    December 2023
33. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    PubMed     Abstract available
    
    
    
34. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    PubMed     Abstract available
    
    
    
35. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    PubMed    
    
    
    
36. DUCHOW A, Bellmann-Strobl J, Friede T, Aktas O, et al
    Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26858.
    PubMed     Abstract available
    
    
    
37. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    PubMed    
    
    
    
38. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    PubMed     Abstract available
    
    
    November 2023
39. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    PubMed     Abstract available
    
    
    October 2023
40. MAJED M, Valencia Sanchez C, Bennett JL, Fryer J, et al
    Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
    Ann Neurol. 2023;94:727-735.
    PubMed     Abstract available
    
    
    September 2023
41. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    PubMed     Abstract available
    
    
    
42. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    PubMed     Abstract available
    
    
    August 2023
43. ADINGUPU DD, Evans T, Soroush A, Hansen A, et al
    Temporal pattern of cortical hypoxia in Multiple Sclerosis and its significance on neuropsychological and clinical measures of disability.
    Ann Neurol. 2023 Aug 22. doi: 10.1002/ana.26769.
    PubMed     Abstract available
    
    
    July 2023
44. SORMANI MP, Schiavetti I, Ponzano M, Colato E, et al
    Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Cognition in Multiple Sclerosis.
    Ann Neurol. 2023 Jul 26. doi: 10.1002/ana.26751.
    PubMed     Abstract available
    
    
    
45. XIE Y, Chen B, Wang Q, Chen X, et al
    Astrocyte-Derived Exosomes Contribute to Pathologies of Neuromyelitis Optica Spectrum Disorder in Rodent Model.
    Ann Neurol. 2023;94:163-181.
    PubMed     Abstract available
    
    
    June 2023
46. YANG B, Brown A, McKeon A, Ahlskog JE, et al
    Tenascin-R autoimmunity: isolated tremor reversed with immunotherapy.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26730.
    PubMed     Abstract available
    
    
    
47. CLARK KA, Manning AR, Chen L, Liu F, et al
    Early MRI features of new paramagnetic rim lesions in Multiple Sclerosis.
    Ann Neurol. 2023 Jun 21. doi: 10.1002/ana.26727.
    PubMed     Abstract available
    
    
    
48. PITTOCK SJ, Barnett M, Bennett JL, Berthele A, et al
    Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Ann Neurol. 2023;93:1053-1068.
    PubMed     Abstract available
    
    
    
49. YIN HX, Wang YJ, Liu MG, Zhang DD, et al
    Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants.
    Ann Neurol. 2023;93:1069-1081.
    PubMed     Abstract available
    
    
    May 2023
50. HOLM HANSEN R, von Essen MR, Mahler MR, Cobanovic S, et al
    Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.
    Ann Neurol. 2023 May 16. doi: 10.1002/ana.26684.
    PubMed     Abstract available
    
    
    
51. PATRICK MT, Nair RP, He K, Stuart PE, et al
    Shared Genetic Risk Factors for Multiple Sclerosis/Psoriasis Suggest Involvement of Interleukin-17 and Janus Kinase-Signal Transducers and Activators of Transcription Signaling.
    Ann Neurol. 2023 May 1. doi: 10.1002/ana.26672.
    PubMed     Abstract available
    
    
    April 2023
52. HAMZAOUI M, Garcia J, Boffa G, Lazzarotto A, et al
    Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression.
    Ann Neurol. 2023 Apr 11. doi: 10.1002/ana.26657.
    PubMed     Abstract available
    
    
    March 2023
53. BAKIRTZIS C, Langdon DW, Grigoriadis N
    Time to rebaseline cognitive performance in people with multiple sclerosis?
    Ann Neurol. 2023 Mar 8. doi: 10.1002/ana.26628.
    PubMed    
    
    
    
54. GALARDI MM, Sowa GM, Crockett CD, Rudock R, et al
    Pathogen and Antibody Identification in Children with Encephalitis in Myanmar.
    Ann Neurol. 2023;93:615-628.
    PubMed     Abstract available
    
    
    February 2023
55. KALLURI HV, Rosebraugh MR, Misko TP, Ziemann A, et al
    Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants.
    Ann Neurol. 2023;93:285-296.
    PubMed     Abstract available
    
    
    January 2023
56. SALVARANI C, Paludo J, Hunder GG, Ansell SM, et al
    Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis.
    Ann Neurol. 2023;93:120-130.
    PubMed     Abstract available
    
    
    
57. STREDNY CM, Blessing MM, Yi V, Ryan ME, et al
    Mimics of Pediatric Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2023;93:109-119.
    PubMed     Abstract available
    
    
    December 2022
58. PAYET CA, You A, Fayet OM, Hemery E, et al
    Central role of macrophages and nucleic acid release in Myasthenia Gravis thymus.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26590.
    PubMed     Abstract available
    
    
    
59. VAN DEN BOSCH AMR, Hummert S, Steyer A, Ruhwedel T, et al
    Ultrastructural Axon-Myelin Unit Alterations in Multiple Sclerosis Correlate with Inflammation.
    Ann Neurol. 2022 Dec 24. doi: 10.1002/ana.26585.
    PubMed     Abstract available
    
    
    
60. ZHANG Y, Zhou Q, Peng L, Chen S, et al
    Increased cerebellum (18) F-DPA-714 uptake in anti-Gluk2-autoimmune encephalitis.
    Ann Neurol. 2022 Dec 8. doi: 10.1002/ana.26563.
    PubMed    
    
    
    
61. NGUYEN S, Bastien E, Chretien B, Sassier M, et al
    Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
    Ann Neurol. 2022;92:1080-1089.
    PubMed     Abstract available
    
    
    November 2022
62. OKUDA DT, Kantarci O, Lebrun-Frenay C, Sormani MP, et al
    Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome.
    Ann Neurol. 2022 Nov 18. doi: 10.1002/ana.26555.
    PubMed     Abstract available
    
    
    
63. GARCIA-MONTOJO M, Simula ER, Fathi S, McMahan C, et al
    Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.
    Ann Neurol. 2022;92:782-792.
    PubMed     Abstract available
    
    
    October 2022
64. VAN KEMPEN ZLE, Hogenboom L, Toorop AA, Steenhuis M, et al
    Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis.
    Ann Neurol. 2022 Oct 17. doi: 10.1002/ana.26534.
    PubMed     Abstract available
    
    
    
65. MURPHY OC, Sotirchos ES, Kalaitzidis G, Vasileiou E, et al
    Trans-synaptic degeneration following acute optic neuritis in multiple sclerosis.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26529.
    PubMed     Abstract available
    
    
    September 2022
66. KELLER CW, Chuquisana O, Derdelinckx J, Gross CC, et al
    Impaired B cell Expression of the Inhibitory Fcgamma Receptor IIB in Myasthenia Gravis.
    Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26507.
    PubMed     Abstract available
    
    
    
67. GAUDIOSO CM, Mar S, Casper TC, Codden R, et al
    MOG and AQP4 antibodies among children with multiple sclerosis and controls.
    Ann Neurol. 2022 Sep 11. doi: 10.1002/ana.26502.
    PubMed     Abstract available
    
    
    August 2022
68. LINDGREN U, Pullerits R, Lindberg C, Oldfors A, et al
    Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis.
    Ann Neurol. 2022;92:201-212.
    PubMed     Abstract available
    
    
    June 2022
69. MAGLIOZZI R, Fadda G, Brown RA, Bar-Or A, et al
    "Ependymal-in" gradient of thalamic damage in progressive multiple sclerosis.
    Ann Neurol. 2022 Jun 24. doi: 10.1002/ana.26448.
    PubMed     Abstract available
    
    
    
70. RAHMANZADEH R, Galbusera R, Lu PJ, Bahn E, et al
    A new advanced MRI biomarker for remyelinated lesions in Multiple Sclerosis.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26441.
    PubMed     Abstract available
    
    
    
71. KOIZUMI N, Takasugi J, Ohara N, Kawamoto M, et al
    FDG-PET/CT of Giant Cell Arteritis With Normal Inflammatory Markers.
    Ann Neurol. 2022 Jun 6. doi: 10.1002/ana.26428.
    PubMed    
    
    
    
72. OECHTERING J, Lincke T, Schaedelin S, Decard BF, et al
    Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
    Ann Neurol. 2022;91:814-820.
    PubMed     Abstract available
    
    
    May 2022
73. CACCIAGUERRA L, Carotenuto A, Pagani E, Mistri D, et al
    MRI EVALUATION OF PERIVASCULAR SPACE ABNORMALITIES IN NEUROMYELITIS OPTICA.
    Ann Neurol. 2022 May 20. doi: 10.1002/ana.26419.
    PubMed     Abstract available
    
    
    
74. ZEYDAN B, Rocca MA, Kantarci OH, Filippi M, et al
    Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Ann Neurol. 2022;91:734-735.
    PubMed    
    
    
    
75. GHIROTTO B, Oliveira DF, Cipelli M, Basso PJ, et al
    MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.
    Ann Neurol. 2022;91:652-669.
    PubMed     Abstract available
    
    
    
76. DIEBOLD M, Galli E, Kopf A, Sanderson N, et al
    Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
    Ann Neurol. 2022;91:676-681.
    PubMed     Abstract available
    
    
    April 2022
77. MANDEL-BREHM C, Benson LA, Tran B, Kung AF, et al
    ZSCAN1 autoantibodies are associated with pediatric paraneoplastic ROHHAD.
    Ann Neurol. 2022 Apr 25. doi: 10.1002/ana.26380.
    PubMed     Abstract available
    
    
    
78. BOSE G, Healy BC, Lokhande HA, Sotiropoulos MG, et al
    Early predictors of clinical and MRI outcomes using LASSO in multiple sclerosis.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26370.
    PubMed     Abstract available
    
    
    
79. IWAMOTO S, Itokazu T, Sasaki A, Kataoka H, et al
    RGMa Signal in Macrophages Induces Neutrophil-Related Astrocytopathy in NMO.
    Ann Neurol. 2022;91:532-547.
    PubMed     Abstract available
    
    
    
80. DOETS AY, Walgaard C, Lingsma HF, Islam B, et al
    International Validation of the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score.
    Ann Neurol. 2022;91:521-531.
    PubMed     Abstract available
    
    
    March 2022
81. KISTER I, Patskovsky Y, Curtin R, Pei J, et al
    Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study.
    Ann Neurol. 2022 Mar 15. doi: 10.1002/ana.26346.
    PubMed     Abstract available
    
    
    
82. LANGER-GOULD A, Cheng SC, Li BH, Smith JB, et al
    Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26352.
    PubMed     Abstract available
    
    
    
83. BRILL L, Raposo C, Rechtman A, Zveik O, et al
    SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab.
    Ann Neurol. 2022 Mar 4. doi: 10.1002/ana.26343.
    PubMed     Abstract available
    
    
    
84. KORNEK B, Leutmezer F, Rommer PS, Koblischke M, et al
    B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients.
    Ann Neurol. 2022;91:342-352.
    PubMed     Abstract available
    
    
    February 2022
85. DE MEO E, Filippi M, Trojano M, Comi G, et al
    Comparing natural history of early and late onset pediatric multiple sclerosis.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26322.
    PubMed     Abstract available
    
    
    
86. ZEKERIDOU A, Yang B, Lennon VA, Guo Y, et al
    Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1.
    Ann Neurol. 2022 Feb 12. doi: 10.1002/ana.26320.
    PubMed     Abstract available
    
    
    
87. MCCOMBE JA, Flanagan EP, Chen JJ, Zekeridou A, et al
    Investigating the Immunopathogenic Mechanisms Underlying MOGAD.
    Ann Neurol. 2022;91:299-300.
    PubMed    
    
    
    January 2022
88. MCKAY KA, Bedri SK, Manouchehrinia A, Stawiarz L, et al
    Reduction in cognitive processing speed surrounding multiple sclerosis relapse.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301.
    PubMed     Abstract available
    
    
    December 2021
89. FLEISCHER V, Ciolac D, Gonzalez-Escamilla G, Grothe M, et al
    Subcortical volumes as early predictors of fatigue in multiple sclerosis.
    Ann Neurol. 2021 Dec 30. doi: 10.1002/ana.26290.
    PubMed     Abstract available
    
    
    
90. BISCHOF A, Papinutto N, Keshavan A, Rajesh A, et al
    Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis.
    Ann Neurol. 2021 Dec 8. doi: 10.1002/ana.26281.
    PubMed     Abstract available
    
    
    
91. HEINE J, Kopp UA, Klag J, Ploner CJ, et al
    Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
    Ann Neurol. 2021;90:949-961.
    PubMed     Abstract available
    
    
    
92. SANTYR B, Pejhan S, Zhang Q, Budhram A, et al
    Unilateral Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2021;90:999-1000.
    PubMed    
    
    
    November 2021
93. ZRZAVY T, Endmayr V, Bauer J, Macher S, et al
    Neuropathological Variability within a Spectrum of NMDAR-Encephalitis.
    Ann Neurol. 2021;90:725-737.
    PubMed     Abstract available
    
    
    
94. QUENDT C, Ochs J, Hausser-Kinzel S, Hausler D, et al
    Proinflammatory CD20(+) T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
    Ann Neurol. 2021;90:834-839.
    PubMed     Abstract available
    
    
    October 2021
95. MARAMATTOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Reply to 'Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis by Dr Pegat et al.
    Ann Neurol. 2021 Oct 27. doi: 10.1002/ana.26257.
    PubMed    
    
    
    
96. PEGAT A, Vogrig A, Khouri C, Masmoudi K, et al
    Adenovirus COVID-19 vaccines and Guillain-Barre syndrome with facial paralysis.
    Ann Neurol. 2021 Oct 26. doi: 10.1002/ana.26258.
    PubMed    
    
    
    
97. TALLANTYRE EC, Vickaryous N, Anderson V, Asardag AN, et al
    COVID-19 vaccine response in people with multiple sclerosis.
    Ann Neurol. 2021 Oct 22. doi: 10.1002/ana.26251.
    PubMed     Abstract available
    
    
    September 2021
98. KOCH MW, Kaur S, Sage K, Kim J, et al
    Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Sep 30. doi: 10.1002/ana.26239.
    PubMed     Abstract available
    
    
    
99. OSOWICKI J, Morgan H, Harris A, Crawford NW, et al
    Guillain-Barre Syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines.
    Ann Neurol. 2021 Sep 15. doi: 10.1002/ana.26218.
    PubMed    
    
    
    
100. ZUHORN F, Graf T, Klingebiel R, Schabitz WR, et al
     Postvaccinal Encephalitis after ChAdOx1 nCov-19.
     Ann Neurol. 2021;90:506-511.
     PubMed     Abstract available
     
     
     August 2021
101. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
     Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
     Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
     PubMed     Abstract available
     
     
     
102. PAN S, Chan JR
     Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
     Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
     PubMed     Abstract available
     
     
     
103. KOLB H, Absinta M, Beck ES, Ha SK, et al
     7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
     Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
     PubMed     Abstract available
     
     
     
104. TEWKESBURY G, Song JW, Perrone CM
     Magnetic Resonance Imaging of Autoimmune GFAP Astrocytopathy.
     Ann Neurol. 2021 Aug 13. doi: 10.1002/ana.26195.
     PubMed    
     
     
     July 2021
105. HANDUNNETTHI L, Knezevic B, Kasela S, Burnham KL, et al
     Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease.
     Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26169.
     PubMed     Abstract available
     
     
     
106. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
     MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
     Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
     PubMed     Abstract available
     
     
     
107. GELIBTER S, Pisa M, Croese T, Finardi A, et al
     Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
     Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
     PubMed     Abstract available
     
     
     
108. HAUSER SL
     Curing Multiple Sclerosis: How to Know When We're There?
     Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
     PubMed    
     
     
     June 2021
109. ALLEN CM, Ramsamy S, Tarr AW, Tighe PJ, et al
     Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination.
     Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26144.
     PubMed     Abstract available
     
     
     
110. MARAMMATOM BV, Krishnan P, Paul R, Padmanabhan S, et al
     Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
     Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26143.
     PubMed     Abstract available
     
     
     
111. HARTUNG HP
     Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
     Ann Neurol. 2021;89:1084-1087.
     PubMed    
     
     
     
112. WINGERCHUK DM, Fujihara K, Palace J, Berthele A, et al
     Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
     Ann Neurol. 2021;89:1088-1098.
     PubMed     Abstract available
     
     
     May 2021
113. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
     Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
     Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
     PubMed     Abstract available
     
     
     
114. BEUKER C, Wankner MC, Thomas C, Strecker JK, et al
     Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype.
     Ann Neurol. 2021 May 16. doi: 10.1002/ana.26101.
     PubMed    
     
     
     
115. LANDA J, Guasp M, Miguez-Cabello F, Guimaraes J, et al
     Encephalitis with autoantibodies against the glutamate kainate receptors GluK2.
     Ann Neurol. 2021 May 5. doi: 10.1002/ana.26098.
     PubMed     Abstract available
     
     
     
116. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
     Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
     Ann Neurol. 2021;89:895-910.
     PubMed     Abstract available
     
     
     April 2021
117. IZUKA S, Kobayashi T, Takahashi Y
     Tongue tremor in systemic lupus erythematosus.
     Ann Neurol. 2021 Apr 21. doi: 10.1002/ana.26088.
     PubMed    
     
     
     
118. COX LM, Maghzi AH, Liu S, Tankou SK, et al
     The Gut Microbiome in Progressive Multiple Sclerosis.
     Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
     PubMed     Abstract available
     
     
     
119. PETZOLD A
     Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
     Ann Neurol. 2021;89:849-850.
     PubMed    
     
     
     
120. WOSTYN P, Gibson CR, Mader TH
     Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
     Ann Neurol. 2021;89:849.
     PubMed    
     
     
     
121. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
     Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
     Ann Neurol. 2021;89:711-725.
     PubMed     Abstract available
     
     
     January 2021
122. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
     The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
     Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.